Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-associated protein 2-deficient TR- rats

Xenobiotica

Volumn 33, Issue 10, 2003, Pages 1027-1044

  Kim, M S ^a   Liu, D Q ^a   Strauss, J R ^a   Capodanno, I ^a   Yao, Z ^a   Fenyk Melody, J E ^a   Franklin, R B ^a   Vincent, S H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RAT STRAIN; STRAIN DIFFERENCE;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0242288637     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250310001602720     Document Type: Article

References (40)

1. BALLATORI, N. and TRUONG, A. T., 1995, Multiple canalicular transport mechanisms for glutathione 5-conjugates. Transport on both ATP-and voltage-dependent carriers. Journal of Biological Chemistry, 270, 3594-3601.
2. CHERRINGTON, N. J., HARTLEY, D. P., LI, N., JOHNSON, D. R. and KLAASSEN, C. D., 2002, Organ distribution of Multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. Journal of Pharmacology and Experimental Therapeutics, 300, 97-104.
3. CURTIS, C. G., DANAHER, T. M., HIBBERT, E. A., MORRIS, C. L., SCOTT, A. M., WOOLCOTT, B. A. and POWELL, G. M., 1985, The fate of gemfibrozil and its metabolites in the rat. Biochemical Society Transactions, 13, 1190-1191.
4. DE VRIES, M. H., REDEGELD, F. A. M., KOSTER, A. S., NOORDHOEK, J., DE HANN, J. G. and OUDE ELFERINK, R. P. J., 1989, Hepatic, intestinal and renal transport of 1-naphthol-β-D-glucuronide in mutant rats with hereditary-conjugated hyperbilirubinemia. Naunyn-Schmiedeberg's Archives of Pharmacology, 340, 588-592.
5. DIETRICH, C. G., DE WAART, D. R., OTTENHOFF, R., BOOTSMA, A. H., VAN GENNIP, A. H. and OUDE ELFERINK, R. P. J., 2001a, Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP). Carcinogenesis, 22, 805-811.
6. DIETRICH, C. G., DE WAART, D. R., OTTENHOFF, R., SCHOOTS, I. G. and OUDE ELFERINK, R. P. J., 2001b, Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Mrp2-deficient rats. Molecular Pharmacology, 59, 974-980.
7. DIX, K. J., COLEMAN, D. P. and JEFFCOAT, A. R., 1999, Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters. Drug Metabolism and Disposition, 27, 138-146.
8. GERK, P. M. and VORE, M., 2002, Regulation of expression of the multidrug resistance associated protein 2 (MRP2) and its role in drug disposition. Journal of Pharmacology and Experimental Therapeutics, 302, 407-415.
9. HIROHASHI, T., ITO, K., OGAWA, K., SUZUKI, H., KUME, K., SHIMIZU, T. and SUGIYAMA, Y., 1998, Hepatic expression of multidrug resistance-associated protein (MRP)-like proteins maintained in Eisai hyperbilirubinemic rats (EHBR). Molecular Pharmacology, 53, 1068-1075.
10. HIROHASHI, T., SUZUKI, K. and SUGIYAMA, Y., 1999, Characterization of the transport properties of cloned rat multidrug resistance associated protein 3 (MRP3). Journal of Biological Chemistry, 274, 15181-15485.
11. ITO, S., IEIRI, I., TANABE, M., SUZUKI, A., HIGUCHI, S. and OTSUBO, K., 2001, Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Phamcogenetics, 11, 175-184.
12. - rats. Research Communications in Molecular Pathology and Pharmacology, 100, 105-116.
13. JANSEN, P. L. M., PERTERS, W. H. and LAMERS, W. H., 1985, Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology, 5, 573-579.
14. KONIG, J., ROST, D., CUI, Y. and KEPPLER, D., 1999, Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology, 29, 1156-1163.
15. KUDO, N., KATAKU, M., SATO, Y. and KAWASHIMA, Y., 2002, Sex hormone-regulated renal transport of perfluorooctanoic acid. Chemico-Biological Interactions, 139, 301-316.
16. KUSUHARA, H. and SUGIYAMA, Y., 2002, Role of transporters in the tissue-selective distribution and elimination of drugs: tranporters in the liver, small intestine, brain and kidney. Journal of Control Release, 78, 43-54.
17. MAYER, R., KARTENBECK, J., BUCHLER, M., JEDLITSCHKY, G., LEIER, I. and KEPPLER, D., 1995, Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence for the canalicular membrane in transport-deficient mutant hepatocytes. Journal of Cell Biology, 131, 137-150.
18. MOR-COHEN, R., ZIVELIN, A., ROSENBERG, N., SHANI, M., MUALLEM, S. and SELIGSOHN, U., 2001, Identification and functional analysis of two mutations in the Multidrug Resistance Protein 2 gene in Israeli patients with Dubin-Johnson syndrome. Journal of Biological Chemistry, 276, 36923-36930.
19. MOTTINO, A. D., HOFFMAN, T., JENNES, L., CAO, J. and VORE, M., 2001, Expression of multidrug resistance-associated protein 2 in small intestine from pregnant and postpartum rats. American Journal of Physiology Gastrointestinal Liver Physiology, 280, G1261-G1273.
20. NIINUMA, K., TAKENAKA, O., HORIE, T., KOBAYASHI, K., KATO, Y., SIZUKI, H. and SUGIYAMA, Y., 1997, Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2-4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4- (3-pyridylmethyl)benzothiazole glucuronide. Journal of Pharmacology and Experimental Therapeutics, 282, 866-872.
21. -) with inherited conjugated hyperbilirubinemia. Journal of Clinical Investigation, 90, 2130-2135.
22. OGAWA, K., SUZUKI, H., HIROHASHI, T., ISHIKAWA, T., MEIER, P. J., HIROSE, K., AKIZAWA, T., YOSHIOKA, M. and SUGIYAMA, Y., 2000, Characterization of inducible nature of MRP3 in rat liver. American Journal of Physiology Gastrointestinal Liver Physiology, 278, G438-G446.
23. OKERHOLM, R. A., KEELEY, F. J., PETERSON, F. E. and GLAZKO, A. J., 1976, The metabolism of gemfibrozil. Proceedings of Royal Society of Medicine, 69 (Suppl. 2), 11-14.
24. OUDE ELFERINK, R. P. J. and JANSEN, P. L. M., 1994, The role of the canalicular multispecific organic anion transporter in the disposal of endo-and xenobiotics. Pharmacology and Therapeutics, 64, 77-97.
25. PAULUSMA, C. C., BOSMA, P. J., ZAMAN, G. J. R., BAKKER, C. T. M., OTTER, M., SCHEFFER, G. L. and SCHEPER, R. J., 1996, Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science, 271, 1126-1128.
26. PAULUSMA, C. C., KOOL, M., BOSMA, P. J., SCHEFFER, G. L., TER BORG, F., SCHEPER, R. J., TYTGAT, G. N. J., BORST, P., BAAS, F. and OUDE ELFERINK, R. P. J., 1997, A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson Syndrome. Hepatology, 25, 1539-1542.
27. PAULUSMA, C. C. and OUDE ELFERINK, R. P. J., 1997, The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. Journal of Molecular Medicine, 75, 420-428.
28. PRUEKSARITANONT, T., ZHAO, J. J., BENNET, M., ROADCAP, B. A., TANG, C., QIU, Y., LIU, L., LIN, J. H., PEARSON, P. G. and BAILLIE, T. A., 2002, Mechanistic studies on metabolic interactions between gemfibrozil and statins. Journal of Pharmacology and Experimental Therapeutics, 301, 1042-1051.
29. RAUCY, J. L. and LASKER, J. M., 1991, Purification of P450 enzymes from human liver. In E. F. John and M. R. Waterman (eds), Methods in Enzymology: Cytochrome P450 (San Diego: Academic Press), 577-587.
30. RENES, J., DE VRIES, E. G. E., JANSEN, P. L. M. and MÜLLER, M., 2000, The (patho) physiological functions of the MRP family. Drug Resistance Updates, 3, 289-302.
31. SALLUSTIO, B. C., SABORDO, L., EVANS, A. M. and NATION, R. L., 2000, Hepatic disposition of electrophilic acyl glucuronide conjugates. Current Drug Metabolism, 1, 163-180.
32. SCHAUB, T. P., KARTENBECK, J., KONIG, J., VOGEL, O., WITZGALL, R., KRIZ, W. and KEPPLER, D., 1997, Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. Journal of the American Society of Nephrology, 8, 1213-1221.
33. SMITH, P. K., KROHN, R. I., HERMANSON, G. T., MALLIA, A. K., GARTNER, F. H., PROVENZANO, M. D., FUJIMOTO, E. K., GOEKE, N. M., OLSON, B. J. and KLENK, D. C., 1985, Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150, 76-85.
34. SPAHN-LANGGUTH, H. and BENET, L., 1992, Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism. Drug Metabolism Review, 24, 5-48.
35. ST-PIERRE, M. V., SERRANO, M. A., MACIAS, R. I., DUBS, U., HOECHLI, M., LAUFER, U., MEIER, P. J. and MARIN, J. J., 2000, Expression of members of the multidrug resistance protein family in human term placenta. American Journal of Physiology Regulatory Integrative and Comparative Physiology, 279, R1495-R1503.
36. THOMAS, B. F., BURGESS, J. P., COLEMAN, D. P., SCHEFFLER, N. M., JEFFCOAT, A. R. and DIX, K. J., 1999, Isolation and identification of novel metabolites of gemfibrozil in rat urine. Drug Metabolism and Disposition, 27, 147-157.
37. TODD, P. A. and WARD, A., 1988, Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs, 36, 314-339.
38. VAN AUBEL, R. A. M. H., MASEREEUW, R. and RUSSEL, F. G. M., 2000, Molecular pharmacology of renal organic anion transporters. American Journal of Physiology and Renal Physiology, 279, F216-F232.
39. WADA, M., TOH, S., TANIGUCHI, K., NAKAMURA, T., UCHIUMI, T., KOHNO, K., YOSHIDA, I., KIMURA, A., SAKISAKA, S., ADACHI, Y. and KUWANO, M., 1998, Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Human Molecular Genetics, 7, 203-207.
40. - rats. Journal of Pharmacology and Experimental Therapeutics, 295, 512-518.